A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Part of paid clinical trials in Denver, Colorado.

Sponsor
Verismo Therapeutics
Study ID
NCT06701201
Status
Enrolling By Invitation

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SynKIR-110 — DRUG
    Autologous T cells Transduced with Mesothelin KIR-CAR
  • SynKIR-310 — DRUG
    Autologous T Cells transduced with CD19 KIR-CAR

Study Details

The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.

Key Dates

Start date
Jan 27, 2025
Status verified
Jan 2026
Primary completion
Feb 28, 2042
Completion
Feb 28, 2042

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: SynKIR-110
    Participants who previously received SynKIR-110 in an interventional trial
  • Arm: SynKIR-310
    Participants who previously received SynKIR-310 in an interventional trial

Primary Outcome Measure

To monitor the long-term safety of participants that have been infused with a SynKIR CAR T cell product [ Time Frame: Up to 15 years from SynKIR CAR T cell product administration ]

Locations (6)

Find similar trials in Denver, CO

Related Studies